Can-Fite BioPharma Ltd. (AMEX: CANF, TASE: CFBI) was founded in 1994 and is headquartered in Petah-Tikva, Israel. It has 7 full-time employees. It is a clinical-stage biopharmaceutical company developed to treat itself Small molecule therapeutic products for immune inflammation, tumors and liver diseases.
Can-Fite BioPharma (CANF):
Can-Fite BioPharma is an Israeli biopharmaceutical company with fully integrated drug discovery and clinical development capabilities. The company has advanced patented compound pipelines in the phase II and phase III clinical development phases, which can solve autoimmune inflammation and cancer diseases .
Sunfit Biopharmaceuticals’ platform technology uses Gi protein-related A3 adenosine receptor (A3AR) as a therapeutic target. A3AR is highly expressed in inflammation and cancer cells, among which low expression is found in normal cells, indicating that this receptor may be a unique target for pharmacological intervention. The company compound binds to A3AR with nM affinity and initiates the deregulation of NF-κB and Wnt signal transduction pathways, thereby producing anti-inflammatory and anti-cancer effects.
Can-Fite BioPharma’s drug product line is a synthetic, highly specific agonist and allosteric modulator for A3AR. All drugs have oral bioavailability and excellent safety.
Canfit Biopharmaceuticals’ product candidates include:
1. CF101 (Piclidenoson) , the main drug candidate of Can-Fite, is currently in phase III clinical trials for the treatment of autoimmune inflammatory diseases, including rheumatoid arthritis (RA) and psoriasis. Can-Fite holds 82% of OphthaliX Inc. (OTCBB: OPLI), which develops CF101 for ophthalmic indications, including dry eye syndrome, glaucoma and uveitis.
Can-Fite has licensed CF101 to Cipher Pharmaceuticals in Canada, Gebro Pharma GmbH in Spain, Switzerland and Austria, and RA to Kwang Dong in South Korea to treat autoimmune diseases.
2. CF102 (Namodenoson) , Can-Fite’s second drug candidate, is being developed for the treatment of liver cancer (primary liver cancer) and non-alcoholic fatty liver disease in the phase II clinical trial phase; also for the treatment of hepatocellular carcinoma And hepatitis C virus disease.
Can-Fite has authorized Chong Kun Dang Pharmaceut in South Korea to use CF102 to treat liver cancer.
3. CF602 , Can-Fite’s second-generation allosteric drug candidate for the treatment of inflammatory diseases, has proven this concept in in vitro and in vivo studies; it is currently in preclinical trials for the treatment of sexual dysfunction
Can-Fite has extensive clinical experience, including more than 1,200 patients participating in the company’s clinical trials.
Can-Fite BioPharma Ltd. and Icahn Medical College reached a cooperative research agreement on the treatment of liver disease.